Genomic Pathology and Cancer Biomarkers: Prostate Cancer. Crit Rev Oncog 2017;22(5-6):515-525
Date
01/01/2017Pubmed ID
29604929DOI
10.1615/CritRevOncog.2017020539Scopus ID
2-s2.0-85059244722 (requires institutional sign-in at Scopus site) 3 CitationsAbstract
Our understanding of genomic pathology and biomarkers for prostate cancer is continually growing. Some promising and useful tissue markers are GSTP1, HOXD3, cell cycle proteins, chromatin remodeling proteins, androgen receptor, Stat5a/b, ERG, and PTEN. Serum and urine markers are mostly either prostate-specific antigen or newer tests using one or more other kallikreins or sarcosine. The data and evidence for all of these markers and the commercial tests using them are reviewed here.
Author List
Iczkowski KAMESH terms used to index this publication - Major topics in bold
Biomarkers, TumorGenomics
Glutathione S-Transferase pi
Homeodomain Proteins
Humans
Kallikreins
Male
Prostate-Specific Antigen
Prostatic Neoplasms
Transcription Factors